Replies to post #218806 on Biotech Values

[DewDiligence]

RLM.L -50% on phase-2 failure:

https://finance.yahoo.com/news/realm-therapeutics-reports-top-line-111800311.html

In a randomized, double-blind, vehicle controlled, Phase 2 clinical trial of 122 patients, PR022 showed no difference from vehicle in the primary endpoint of percent change in Eczema Area Severity Index (EASI) versus baseline.